Tanaka Yuka 田中由香

… Alternative Names

田中由香タナカユカ

Less

Researcher Number	00746464
Affiliation (Current)	2025: 九州大学, 医学研究院, 助教
Affiliation (based on the past Project Information) *help	2022 – 2023: 九州大学, 大学病院, 学術研究員
Review Section/Research Field	Principal Investigator Basic Section 53050:Dermatology-related
Keywords	Principal Investigator マイクロアレイ / 標的分子 / 皮膚悪性腫瘍 / 抗体薬物複合体

Establishment and validation of the methods for the production of antibody-drug conjugates against malignant skin tumorsPrincipal Investigator
- Principal Investigator
  
  田中由香
- Project Period (FY)
  2022 – 2024
- Research Category
  
  Grant-in-Aid for Early-Career Scientists
- Review Section
  
  Basic Section 53050:Dermatology-related
- Research Institution
  Kyushu University

All 2024 2023 2022

All Journal Article Presentation

[Journal Article] NECTIN4‐targeted antibody?drug conjugate is a potential therapeutic option for extramammary Paget disease2024
- Author(s)
  Tanaka Yuka、Ito Takamichi、Murata Maho、Tanegashima Keiko、Kaku‐Ito Yumiko、Nakahara Takeshi
- Journal Title
  
  Experimental Dermatology
  
  Volume: 33 Issue: 3 Pages: 0-0
- DOI
  10.1111/exd.15049
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K15543, KAKENHI-PROJECT-22K16283
[Journal Article] Human epidermal growth factor receptor 3 serves as a novel therapeutic target for acral melanoma2023
- Author(s)
  Tanaka Yuka、Ito Takamichi、Kaku-Ito Yumiko、Tanegashima Keiko、Tsuji Gaku、Kido-Nakahara Makiko、Oda Yoshinao、Nakahara Takeshi
- Journal Title
  
  Cell Death Discovery
  
  Volume: 9 Issue: 1 Pages: 0-0
- DOI
  10.1038/s41420-023-01358-5
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K16283, KAKENHI-PROJECT-22K15543
[Journal Article] Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcoma2022
- Author(s)
  Tanaka Yuka、Murata Maho、Tanegashima Keiko、Oda Yoshinao、Ito Takamichi
- Journal Title
  
  Scientific Reports
  
  Volume: 12 Issue: 1
- DOI
  10.1038/s41598-022-07727-x
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K16283, KAKENHI-PROJECT-19H03444
[Presentation] Human epidermal growth factor receptor 3 regulates anchorage-independent growth of acral melanoma cells and serves as a novel therapeutic target.2023
- Author(s)
  Tanaka Yuka, Ito Takamichi, Kaku-Ito Yumiko, Tanegashima Keiko, Tsuji Gaku, Nakahara-Kido Makiko, Nakahara Takeshi
- Organizer
  International Societies for Investigative Dermatology Meeting 2023
- Data Source
  KAKENHI-PROJECT-22K16283
[Presentation] Nectin cell adhesion molecule 4 regulates angiogenesis and serves as a novel therapeutic target in angiosarcoma2022
- Author(s)
  Tanaka Yuka、Ito Takamichi、Tanegashima Keiko、Tsuji Gaku、Nakahara Makiko、Nakahara Takeshi
- Organizer
  日本研究皮膚科学会第47回年次学術大会・総会
- Data Source
  KAKENHI-PROJECT-22K16283

1. 伊東孝通

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Tanaka Yuka 田中由香

田中由香タナカユカ

Research Projects

Research Products

Co-Researchers

Establishment and validation of the methods for the production of antibody-drug conjugates against malignant skin tumorsPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

[Journal Article] NECTIN4‐targeted antibody?drug conjugate is a potential therapeutic option for extramammary Paget disease2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Human epidermal growth factor receptor 3 serves as a novel therapeutic target for acral melanoma2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcoma2022

Author(s)

Journal Title

DOI

Data Source

[Presentation] Human epidermal growth factor receptor 3 regulates anchorage-independent growth of acral melanoma cells and serves as a novel therapeutic target.2023

Author(s)

Organizer

Data Source

[Presentation] Nectin cell adhesion molecule 4 regulates angiogenesis and serves as a novel therapeutic target in angiosarcoma2022

Author(s)

Organizer

Data Source

Tanaka Yuka 田中 由香

田中 由香 タナカ ユカ

Research Projects

Research Products

Co-Researchers

Establishment and validation of the methods for the production of antibody-drug conjugates against malignant skin tumorsPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

[Journal Article] NECTIN4‐targeted antibody?drug conjugate is a potential therapeutic option for extramammary Paget disease2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Human epidermal growth factor receptor 3 serves as a novel therapeutic target for acral melanoma2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcoma2022

Author(s)

Journal Title

DOI

Data Source

[Presentation] Human epidermal growth factor receptor 3 regulates anchorage-independent growth of acral melanoma cells and serves as a novel therapeutic target.2023

Author(s)

Organizer

Data Source

[Presentation] Nectin cell adhesion molecule 4 regulates angiogenesis and serves as a novel therapeutic target in angiosarcoma2022

Author(s)

Organizer

Data Source

Tanaka Yuka 田中由香

田中由香タナカユカ